Zobrazeno 1 - 10
of 38
pro vyhledávání: '"LOWELL B. ANTHONY"'
Autor:
Aaron S. Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama N. Waqar, Andrew E. Hendifar, Lowell B. Anthony, Matthew H. Taylor, Alan H. Bryce, Scott T. Tagawa, Karl Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, Rahul Aggarwal
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-7 (2021)
Abstract Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other
Externí odkaz:
https://doaj.org/article/41cea5032a0d44ac9ceef9a9bed44b7a
Autor:
Talal Hilal, Mary Nakazawa, Jacob Hodskins, John L. Villano, Aju Mathew, Guarav Goel, Lars Wagner, Susanne M. Arnold, Philip DeSimone, Lowell B. Anthony, Peter J. Hosein
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Describe a single-center real-world experience with comprehensive genomic profiling (CGP) to identify genotype directed therapy (GDT) options for patients with malignancies refractory to standard treatment options. Methods Patient
Externí odkaz:
https://doaj.org/article/5a9279e6648841599a63ee8110806fc2
Autor:
Hala E. Thomas, Jack Rubinstein, Lowell B. Anthony, Carol A. Mercer, Xiaoyang Qi, Kakajan Komurov, David R. Plas, Hanan M. Dahche, Vinicius S. Carreira, Sheryl E. Koch, Kathleen LaSance, Mariah Worley, Min Jiang, Zhengtao Chu, Melissa A. Orr-Asman
Inhibition of mTOR signaling using the rapalog everolimus is an FDA-approved targeted therapy for patients with lung and gastroenteropancreatic neuroendocrine tumors (NET). However, patients eventually progress on treatment, highlighting the need for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64aae7793335e011bc4ba3984f311be0
https://doi.org/10.1158/1535-7163.c.6538789
https://doi.org/10.1158/1535-7163.c.6538789
Autor:
Hala E. Thomas, Jack Rubinstein, Lowell B. Anthony, Carol A. Mercer, Xiaoyang Qi, Kakajan Komurov, David R. Plas, Hanan M. Dahche, Vinicius S. Carreira, Sheryl E. Koch, Kathleen LaSance, Mariah Worley, Min Jiang, Zhengtao Chu, Melissa A. Orr-Asman
Table S1. CC-223-treated mice tend to develop less histopathologic lesions of the heart valves than either rapamycin- or placebo-treated mice. Figure S1. MLN0128 inhibited mTOR signaling in human pNET cell lines in a dose-dependent manner. Figure S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d90b178ee84c8bf4d1cc19a4cbef7c1
https://doi.org/10.1158/1535-7163.22507783
https://doi.org/10.1158/1535-7163.22507783
Autor:
Scott T. Tagawa, Karl D. Lewis, Christine H. Chung, Himisha Beltran, Ricardo Valenzuela, Jiaxin Niu, Christine L. Hann, Andrew Eugene Hendifar, David S. Hong, Rahul Aggarwal, Aaron S. Mansfield, Michael Rossi, Anna F. Farago, Saiama N. Waqar, Carrianne Ludwig, Lowell B. Anthony, James M. Cleary, Matthew H. Taylor, Alan H. Bryce, Yan Luo
Publikováno v:
NPJ Precision Oncology
npj Precision Oncology, Vol 5, Iss 1, Pp 1-7 (2021)
npj Precision Oncology, Vol 5, Iss 1, Pp 1-7 (2021)
3552 Background: Delta-like 3 (DLL3) is highly and specifically expressed in solid tumors, such as neuroendocrine carcinomas (NECs), malignant melanoma (MM), and medullary thyroid carcinoma (MTC). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31bbbf3d0ae98b96b59048042d5aeb36
http://europepmc.org/articles/PMC8342450
http://europepmc.org/articles/PMC8342450
Publikováno v:
The American Journal of the Medical Sciences. 357:258-262
We present a rare high-grade, functional, neuroendocrine carcinoma of the pancreas secreting vasoactive intestinal peptide. This case is unique, given the tumor's aggressive features and high Ki-67 index while also secreting functional hormones, whic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2f374269c0e6d30e10ccb28cea549fb
https://doi.org/10.1016/j.amjms.2018.11.001
https://doi.org/10.1016/j.amjms.2018.11.001
Autor:
Aman Chauhan, Kurt B Hodges, B. Mark Evers, Zin W. Myint, Scott R. Silva, Zainab Farooqui, Heidi L. Weiss, Susanne M. Arnold, Arumugam K Raajesekar, Qian Yu, Le Aundra Murray, Lowell B. Anthony
Publikováno v:
Asian Pacific Journal of Cancer Prevention : APJCP
Background: Neuroendocrine tumors (NETs) are rare tumors that can originate from any part of the body. Often, imaging or exploratory surgery can assist in the identification of the tumor primary site, which is critical to the management of the diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86cc7f120f80294b98f501a1b504f92b
https://doi.org/10.31557/apjcp.2019.20.1.113
https://doi.org/10.31557/apjcp.2019.20.1.113
Autor:
Kurt R. Oettel, Edward L. Nelson, Merry Jennifer Markham, Claire F. Verschraegen, Lisa A. Carey, Julie M. Vose, George F. Atweh, Wells A. Messersmith, Martin J. Edelman, Philip W. Kantoff, Ruth O'Regan, Jenny C. Chang, Ravi Bhatia, Lowell B. Anthony
Publikováno v:
JCO Oncol Pract
JCO oncology practice, vol 17, iss 3
JCO oncology practice, vol 17, iss 3
The role of clinical researchers is vital to cancer progress. The teaching, research, and leadership roles that academic oncologists hold need to be accounted for and appropriately compensated. National metrics are currently inexistent, but are neces
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eab7d6f1db9f42484f88563581d4168a
https://europepmc.org/articles/PMC8462569/
https://europepmc.org/articles/PMC8462569/
Publikováno v:
Lung. 196:577-581
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare pulmonary condition, characterized by diffuse proliferation of neuroendocrine cells in the respiratory epithelium. DIPNECH lesions are less than 5 mm in size and are lim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39e61cef8129ece5d1ee65b8734ddb36
https://doi.org/10.1007/s00408-018-0149-z
https://doi.org/10.1007/s00408-018-0149-z
Autor:
Dima Hnoosh, Bin Huang, Hayder Saeed, Sean P. Dineen, Lowell B. Anthony, Ching Wei D. Tzeng, Peter J. Hosein, Philip A. DeSimone, Erin Maynard, Eric B. Durbin, Patrick C. McGrath
Publikováno v:
Journal of Surgical Oncology. 114:451-455
Background Long-term results of the ESPAC-3 trial suggest that while completing adjuvant therapy (AT) is necessary after resection of pancreatic ductal adenocarcinoma (PDAC), early initiation (within 8 weeks) may not be associated with improved overa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::743e96ab66c9d10a4b077f81f530f35e
https://doi.org/10.1002/jso.24314
https://doi.org/10.1002/jso.24314